
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Rana McKay, MD, describes the CheckMate-214, KEYNOTE-426, CheckMate-9ER, and CLEAR trials, which she says, “have largely changed the way we treat kidney cancer in the modern era for patients with advanced/metastatic disease.” McKay is a medical oncologist and associate professor of Medicine at the University of California San Diego, Moores Cancer Center.